Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Osstem USII plus ÀÓÇöõÆ®ÀÇ ´Ü±â°£ ¼º°ø·ü ¹× º¯¿¬°ñ Èí¼ö·® Æò°¡

Success rate and marginal bone loss of Osstem USII plus implants; Short term clinical study

´ëÇÑÄ¡°úº¸Ã¶ÇÐȸÁö 2011³â 49±Ç 3È£ p.206 ~ 213
±è¼±±Ù, ±èÁöȯ, À̱ٿì, Á¶±Ô¼º, Çѵ¿ÈÄ,
¼Ò¼Ó »ó¼¼Á¤º¸
±è¼±±Ù ( Kim Sun-Keun ) - ¿¬¼¼´ëÇб³ Ä¡°ú´ëÇÐ º¸Ã¶°úÇб³½Ç
±èÁöȯ ( Kim Jee-Hwan ) - ¿¬¼¼´ëÇб³ Ä¡°ú´ëÇÐ º¸Ã¶°úÇб³½Ç
À̱ٿì ( Lee Keun-Woo ) - ¿¬¼¼´ëÇб³ Ä¡°ú´ëÇÐ Ä¡°úº¸Ã¶Çб³½Ç
Á¶±Ô¼º ( Cho Kyoo-Sung ) - ¿¬¼¼´ëÇб³ Ä¡°ú´ëÇÐ Ä¡ÁÖ°úÇб³½Ç
Çѵ¿ÈÄ ( Han Dong-Hoo ) - ¿¬¼¼´ëÇб³ Ä¡°ú´ëÇÐ Ä¡°úº¸Ã¶Çб³½Ç

Abstract

¿¬±¸¸ñÀû:ÀÓÇöõÆ® °æºÎ±îÁöRBM Ç¥¸é 󸮸¦ ÇÑ OsstemUSII plus system (Osstem Co., Seoul, Korea)ÀÇ ÀÓ»óÀû À¯¿ë¼ºÀ» Æò°¡Çϱâ À§ÇÏ¿© ¿¬¼¼´ëÇб³ Ä¡°ú´ëÇÐ º´¿ø¿¡ ³»¿øÇÑ È¯ÀÚ Áß ÀÌ systemÀ» ÀÌ¿ëÇÏ¿© Ä¡·á ¹ÞÀº 32¸íÀÇ È¯ÀÚ¿¡°Ô ½Ä¸³µÈ 88°³ÀÇ ÀÓÇöõÆ®¸¦ ´ë»óÀ¸·Î ±â´É ºÎÇÏ ÈÄ 1³â±îÁöÀÇ ÀÓ»óÀû, ¹æ»ç¼±ÇÐÀû °á°ú¸¦ ÈÄÇâÀûÀ¸·Î ºÐ¼®ÇÏ¿´´Ù.

¿¬±¸ Àç·á ¹× ¹æ¹ý:Áø·á ±â·ÏºÎ¸¦ ÅëÇØ Àü½Å Á¶°Ç, ¼ºº°, ¿¬·É, ½Ä¸³ À§Ä¡, ½Ä¸³ µÈ ÀÓÇöõÆ®ÀÇ Á÷°æ ¹× ±æÀÌ µîÀ» Á¶»çÇÏ¿© ±×¿¡ µû¸¥ ºÐÆ÷ ¹× »ýÁ¸À²ÀÇ Â÷ÀÌ¿Í ÇÔ²² À̵é Ç׸ñÀÌ º¯¿¬°ñ Èí¼ö·®¿¡ ¿µÇâÀ» ¹ÌÄ¡´ÂÁö Á¶»çÇÏ¿´´Ù. ¹æ»ç¼±»çÁø ºÐ¼®À¸·Î ÀÓÇöõÆ® ½Ä¸³ ½Ã, º¸Ã¶¹° ÀåÂø ÈÄ 6°³¿ù ³»Áö 1³â°£ÀÇ º¯¿¬°ñ Èí¼ö·®À» ÃøÁ¤ÇÏ¿© ºÐ¼®ÇÏ¿´´Ù. °¢ Ç׸ñ°úÀÇ ¿¬°ü¼º ºÐ¼®À» À§ÇÏ¿© µ¶¸³ t-°ËÁ¤(independent sample t-test)À» ÀÌ¿ëÇÏ¿´À¸¸ç(¥á=.05), º¸Ã¶¹° ÀåÂø Àü°ú º¸Ã¶¹° ÀåÂø ÈÄ 12°³¿ù µ¿¾ÈÀÇ º¯¿¬°ñ Èí¼ö·® ºñ±³¸¦ À§ÇÏ¿© ÀÏ¿ø ¹Ýº¹ÃøÁ¤ ºÐ»ê ºÐ¼®(one-way repeated-measures ANOVA)À» ÀÌ¿ëÇÏ¿´´Ù(¥á=.05).

°á°ú:ÃÑ 32¸í¿¡°Ô ½Ä¸³µÈ 88°³ÀÇ ÀÓÇöõÆ® Áß¿¡¼­ ½ÇÆÐÇÑ °ÍÀº ¾ø¾úÀ¸¸ç ´©Àû »ýÁ¸À²Àº 100%·Î ³ªÅ¸³µ´Ù. ÀÓÇöõÆ® ½Ä¸³ ½ÃºÎÅÍ º¸Ã¶¹° ÀåÂø±îÁöÀÇ º¯¿¬°ñ Èí¼ö·®Àº 0.24 mmÀ̾úÀ¸¸ç, º¸Ã¶¹° ÀåÂø ÈÄ 12°³¿ù±îÁöÀÇ º¯¿¬°ñ Èí¼ö·®Àº Æò±Õ 0.19 mm·Î ÀÓÇöõÆ® ½Ä¸³ ½ÃºÎÅÍ º¸Ã¶¹° ÀåÂø 12°³¿ù±îÁöÀÇ ÃÑ º¯¿¬°ñ Èí¼ö·®Àº 0.43 mm¿´´Ù. »ó¾Ç¿¡ ½Ä¸³µÈ °æ¿ì¿Í ÇϾǿ¡ ½Ä¸³µÈ °æ¿ìÀÇ º¯¿¬°ñ Èí¼ö·®À» ºñ±³ÇßÀ» ¶§´Â Åë°èÀûÀ¸·Î À¯ÀÇÇÑ Â÷À̸¦ º¸ÀÌÁö ¾Ê¾ÒÀ¸³ª ±¸Ä¡ºÎ¿¡ ½Ä¸³µÈ °æ¿ì°¡ ÀüÄ¡ºÎ¿¡ ½Ä¸³µÈ °æ¿ì¿¡ ºñÇØ º¯¿¬°ñ Èí¼ö·®ÀÌ Å©°Ô ³ªÅ¸³µÀ¸¸ç ÀÌ´Â Åë°èÀûÀ¸·Î À¯ÀÇÇÑ Â÷ÀÌ°¡ ÀÖ¾ú´Ù.

°á·Ð:ÀÌ»óÀÇ °á°ú¸¦ Åä´ë·Î º¸Ã¶¹° ÀåÂø 12°³¿ù±îÁöÀÇ ±â°£ µ¿¾È ÀÓÇöõÆ® °íÁ¤Ã¼ÀÇ °æºÎ±îÁö RBM Ç¥¸é 󸮸¦ ÇÑ ¿ÜÃø ¿¬°áÇüÀÇ ±¹»ê ÀÓÇöõÆ®ÀÇ ´Ü±â°£ ÀÓ»óÀûÀÎ ¼º°ø·üÀº ¸¸Á·½º·¯¿î °á°ú¸¦ º¸¿´À¸¸ç º¯¿¬°ñ Èí¼ö·®µµ ÀÓÇöõÆ® ¼º°ø ±âÁØ¿¡ ºÎÇÕÇÏ¿´´Ù.

Purpose: The aim of this study was to evaluate the clinical value of Osstem. USII plus system implants. Clinical and radiographic data were analyzed for 88 implants placed and functionally loaded for a 12 month period at the Yonsei University Dental Hospital.

Materials and Methods: Based on the patient¡¯s medical records, clinical factors and their effects on implant marginal bone resorption, distribution and survival rate were analyzed. The marginal bone loss was evaluated at implant placement and during a 6 to 12 months functional loading period. The independent sample t-test was used to evaluate the interrelationship between the factors (¥á=0.05), and one way repeated measures ANOVA was used to compare the amount of marginal bone resorption.

Results: The cumulative survival rate for 88 implants was 100%. The marginal bone resorption from implant placement to prosthetic delivery was 0.24 mm and the average marginal bone resorption from prosthetic delivery to 12 months of functional loading was 0.19 mm. The total average bone resorption from implant placement to 12 months of functional loading was 0.43 mm. There were no statistically differences in the amount of marginal bone resorption when implants were placed in the maxilla or the mandible (P>.05), however, implants placed in the posterior areas showed significantly more marginal bone loss than those placed in the anterior areas (P<.05).

Conclusion:Based on these results, the short term clinical success rate of RBM surface treated external connection domestic implants showed satisfactory results and the marginal bone loss was in accord with the success criteria of dental implants.

Å°¿öµå

±¹»ê ÀÓÇöõÆ®; RBM Ç¥¸é; ¿ÜÃø ¿¬°áÇü; »ýÁ¸À²; º¯¿¬°ñ Èí¼ö
RBM surface; External connection; Survival rate; Marginal bone loss

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed